Of the patients that received biological treatment for psoriasis with an anti-IL-17 agent, 12.5% (n = 3/24) received systemic corticosteroids, 8.3% (n = 2/24) received a Janus Kinase (JAK) inhibitor and 25% (n = 6/24) were not prescribed concomitant systemic therapy for AD. This evidence concerns the gene IL17A and psoriasis.